Premium
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy
Author(s) -
van der Kwast T. H.,
Têtu B.,
Fradet Y.,
Dupont A.,
Gomez J.,
Cusan L.,
Diamond P.,
Labrie F.
Publication year - 1996
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(199604)28:4<227::aid-pros3>3.0.co;2-a
Subject(s) - medicine , androgen receptor , prostate , neoadjuvant therapy , endocrine system , prostatic adenocarcinoma , oncology , urology , androgen , prostate cancer , adenocarcinoma , antiandrogen , cancer research , endocrinology , cancer , hormone , breast cancer
Modulation of androgen receptor (AR) expression during neoadjuvant endocrine therapy in human prostates of patients with localized prostate cancer was investigated by immunohistochemistry. In 8 of 15 untreated prostatectomy specimens, the majority of prostatic glandular cells displayed nuclear immunostaining for AR, whereas only 1 of 26 pretreated cases displayed a similar glandular AR expression. Expression of AR in the prostatic stromal compartment of nontreated cases proved to be quite heterogeneous, since 4 of the 15 (27%) examined specimens did not show stromal AR expression. After preoperative neoadjuvant therapy, this value was 68%, although this difference did not reach statistical significance. Prostatectomy specimens of the treated patients contained carcinomas with a higher Gleason score than those of untreated patients. AR expression in carcinomas of treated patients was diminished ( P =0.05), which may be attributed to their relatively lower differentiation grade. The data strongly suggest that neoadjuvant hormone therapy reduces AR expression by nonneoplastic prostatic glandular cells and carcinoma cells by a selective, but incomplete, elimination of AR‐positive cells. © 1996 Wiley‐Liss, Inc.